Increased CD39 expression on CD4 + T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia

Annals of Hematology

Volumn 91, Issue 8, 2012, Pages 1271-1279

  Perry, Chava ^a   Hazan Halevy, Inbal ^a   Kay, Sigi ^a   Cipok, Michal ^a   Grisaru, Dan ^a,b   Deutsch, Varda ^a   Polliack, Aaron ^a,c   Naparstek, Elizabeth ^a,b   Herishanu, Yair ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

ATP; CD39; CLL; Immune modulation; Tcells

Indexed keywords

ADENOSINE TRIPHOSPHATE; B LYMPHOCYTE RECEPTOR; BETA 2 MICROGLOBULIN; CD39 ANTIGEN; CD4 ANTIGEN; ECTONUCLEOTIDASE CD39; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 2 RECEPTOR ALPHA; NUCLEOTIDASE; PROTEIN KINASE ZAP 70; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

AGED; ANALYTICAL PARAMETERS; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CD4+ T LYMPHOCYTE; CELL STIMULATION; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; ENZYME INDUCTION; FEMALE; FOLLOW UP; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOGLOBULIN HEAVY CHAIN VARIABLE REGION GENE; IN VITRO STUDY; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TIME TO TREATMENT; TUMOR MICROENVIRONMENT;

AGED; ANTIGENS, CD; ANTIGENS, SURFACE; APYRASE; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84864981585     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1425-2     Document Type: Article

References (32)

1. Byrd JC, Stilgenbauer S, Flinn IW (2004) Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 163-183
2. Curiel TJ (2007) Tregs and rethinking cancer immunotherapy. J Clin Invest 117:1167-1174 (Pubitemid 46718401)
3. Lapalombella R, Andritsos L, Liu Q et al (2010) Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinasedependent pathway. Blood 115:2619-2629
4. Molica S (2007) Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm. Leuk Lymphoma 48:866-869 (Pubitemid 47161556)
5. Ramsay AG, Johnson AJ, Lee AM et al (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 118:2427-2437 (Pubitemid 351949771)
6. + Treg cells: Hydrolysis of extracellular ATP and immune suppression. Blood 110:1225-1232 (Pubitemid 47281420)
7. Mizumoto N, Kumamoto T, Robson SC et al (2002) CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat Med 8:358-365 (Pubitemid 34407030)
8. Bours MJ, Swennen EL, Di Virgilio F et al (2006) Adenosine 5′- triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112:358-404 (Pubitemid 44486409)
9. Deaglio S, Dwyer KM, Gao W et al (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204:1257-1265 (Pubitemid 46919862)
10. Langston HP, Ke Y, Gewirtz AT et al (2003) Secretion of IL-2 and IFN-gamma, but not IL-4, by antigen-specific T cells requires extracellular ATP. J Immunol 170:2962-2970 (Pubitemid 36302168)
11. Thiel M, Caldwell CC, Sitkovsky MV (2003) The critical role of adenosine A2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases. Microbes Infect 5:515-526 (Pubitemid 36570479)
12. +-infiltrating T cells contribute to adenosinemediated T cell hyporesponsiveness. J Immunol 183:6157-6166
13. Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108:804-811 (Pubitemid 44154611)
14. Darrasse-Jeze G, Deroubaix S, Mouquet H et al (2009) Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med 206:1853-1862
15. Gobert M, Treilleux I, Bendriss-Vermare N et al (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69:2000-2009
16. Giannopoulos K, Schmitt M, Kowal M et al (2008) Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 20:677-682
17. D'Arena G, Laurenti L, Minervini MM et al (2011) Regulatory Tcell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res 35:363-368
18. Weiss L, Melchardt T, Egle A et al (2011) Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 117:2163-2169
19. Christopoulos P, Pfeifer D, Bartholome K et al (2011) Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. J Am Soc Hematol 117(14):3836-3846
20. + regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors. J Immunol 175:3075-3083 (Pubitemid 41170527)
21. Moncrieffe H, Nistala K, Kamhieh Yet al (2010) High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population. J Immunol 185:134-143
22. Hallek M, Cheson BD, Catovsky D et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456
23. Mao Z, Quintanilla-Marti L, Raffeld M et al (2007) IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol 31:1605-1614 (Pubitemid 47482476)
24. Herishanu Y, Perez-Galan P, Liu D et al (2011) The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117:563-574
25. Crespo M, Bosch F, Villamor N et al (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764-1775 (Pubitemid 36514707)
26. + regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 139(3):1030-1040
27. + T cells by producing CCL22. Eur J Immunol 32:1403-1413 (Pubitemid 34546268)
28. Ohta A, Gorelik E, Prasad SJ et al (2006) A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A 103:13132-13137 (Pubitemid 44338928)
29. Blay J, White TD, Hoskin DW (1997) The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 57:2602-2605 (Pubitemid 27283766)
30. Gorini S, la Sala A (2008) Hydrolysis of extracellular ATP and immune suppression: humans versus mice. Blood 111:965-966
31. Pulte D, Furman RR, Broekman MJ et al (2011) CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leukemia 4:367-372
32. Quiroga MP, Balakrishnan K, Kurtova AV et al (2009) B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 114:1029-1037